Misplaced Pages

Anacetrapib

Names
Preferred IUPAC name (4S,5R)-5--3-{-2-yl]methyl}-4-methyl-1,3-oxazolidin-2-one
Other names MK-0859
Identifiers
CAS Number	875446-37-0
3D model (JSmol)	Interactive image
ChEMBL	ChEMBL1800807
ChemSpider	9731205
KEGG	D08855
PubChem CID	11556427
UNII	P7T269PR6S
CompTox Dashboard (EPA)	DTXSID90236452
InChI InChI=1S/C30H25F10NO3/c1-14(2)22-11-23(25(43-4)12-24(22)31)21-6-5-18(28(32,33)34)9-17(21)13-41-15(3)26(44-27(41)42)16-7-19(29(35,36)37)10-20(8-16)30(38,39)40/h5-12,14-15,26H,13H2,1-4H3/t15-,26-/m0/s1Key: MZZLGJHLQGUVPN-HAWMADMCSA-N InChI=1/C30H25F10NO3/c1-14(2)22-11-23(25(43-4)12-24(22)31)21-6-5-18(28(32,33)34)9-17(21)13-41-15(3)26(44-27(41)42)16-7-19(29(35,36)37)10-20(8-16)30(38,39)40/h5-12,14-15,26H,13H2,1-4H3/t15-,26-/m0/s1Key: MZZLGJHLQGUVPN-HAWMADMCBN
SMILES O=C2O(c1cc(cc(c1)C(F)(F)F)C(F)(F)F)(N2Cc4c(c3cc(c(F)cc3OC)C(C)C)ccc(c4)C(F)(F)F)C
Properties
Chemical formula	C30H25F10NO3
Molar mass	637.51 g·mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa). N verify (what is  ?) Infobox references

Anacetrapib is a CETP inhibitor which was being developed to treat elevated cholesterol levels in an effort to prevent cardiovascular disease. In 2017 its development was abandoned by Merck.

Evidence

In 2017 REVEAL trial anacetrapib was shown to decrease the risk of repeat heart attacks in high-risk patients with previous acute coronary events.

See also

Other CETP inhibitors:

• Torcetrapib was developed by Pfizer until December 2006 but caused unacceptable increases in blood pressure and had net cardiovascular detriment.
• Dalcetrapib was developed by Hoffmann–La Roche until May 2012. It did not raise blood pressure and did raise HDL, but it showed no clinically meaningful efficacy.
• Evacetrapib was developed by Eli Lilly and Company until October 2015.

References

1. Gutstein DE, Krishna R, Johns D, et al. (2012). "Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction". Clinical Pharmacology & Therapeutics. 91 (1): 109–122. doi:10.1038/clpt.2011.271. PMID 22130116. S2CID 36510986.
2. "Merck says will not seek approval of cholesterol treatment". Reuters. 2017. Retrieved 18 October 2017.
3. Filippatos, TD; Kei, A; Elisaf, MS (29 September 2017). "Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?". Diseases. 5 (4): 21. doi:10.3390/diseases5040021. PMC 5750532. PMID 28961179.

Further reading

• WO 2007005572, Miller, Ross A. & Cote, Aaron S., "Process for synthesizing a CETP inhibitor", published 2007-01-11, assigned to Merck & Co. Inc. 

• Trifluoromethyl compounds
• 2-Oxazolidinones
• O-methylated phenols
• Experimental drugs
• Fluoroarenes
• Isopropyl compounds
• Abandoned drugs
• CETP inhibitors